Key Drivers
- Strong Liquidity
- Weak Profitability
- High Leverage
AIAI Summary
Tempus is no longer just a high-growth health-tech story; it is now a proving ground for whether revenue momentum and pharma partnerships can generate operating leverage fast enough to offset persistent losses, negative free cash flow, and financing/dilution risk, with the recent break below support signaling that investors want profits—not just growth—before re-rating the stock.
Price Chart
Financial Metrics
Deep Analysis
Research tool. Not personalized advice.
Fundamental Analysis
Key Financial Insights:
- •Strong Liquidity
- •Weak Profitability
- •High Leverage
TEM has strong gross margins and solid liquidity, but persistent losses, weak returns, high leverage, and a premium valuation keep the investment case risky.
Price Behavior
Key Price Behavior Insights:
- •Lower highs
- •Support breakdown
- •Weak rebound
TEM has rolled over from an uptrend into a clear downtrend over the last month after breaking $49.5-$50.0 support, with $43.9-$45.0 now the key near-term hold zone.
Sharp selloff from
Sentiment & News
Key News Insights:
- •Revenue Growth
- •Loss Narrowing
- •Convertible Funding
Tempus AI posted strong revenue growth and improving diagnostics momentum, but investors remain focused on persistent losses, rising costs, and valuation as it works toward profitability.
The news is modestly positive for long-term growth but likely keeps near-term pressure on the stock until Tempus shows clearer profit improvement
Similar Companies in Healthcare
Other companies in the same sector with AI ratings